Short answer
Thermo Fisher Scientific (TMO) filed its Q1 2026 10-Q quarterly report on May 1, 2026 for the quarter ended Mar 28, 2026. Quarterly revenue was $11.0B (up 6.2% year over year) with net income of $1.7B.
Q1 2026 key financials · XBRL
- Revenue
- $11.0B
- +6.2% YoY
- Net income
- $1.7B
- +9.6% YoY
- Operating margin
- 16.9%
- EPS (diluted)
- $4.43
- +11.3% YoY
Source: XBRL data from the Thermo Fisher Scientific (TMO) Q1 2026 10-Q on SEC EDGAR. USD.
Thermo Fisher Scientific Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $11.005B, up 6% YoY from $10.364B; organic growth 1%
- GAAP operating margin 16.9% vs 16.6%; adjusted margin 21.8% vs 21.9%
- Best segment Life Sciences Solutions revenue $2.636B, up 13%; margin 36.2% vs 35.6%
- Worst segment Analytical Instruments revenue $1.716B, flat; margin 20.7% vs 23.2%
- Operating cash flow $1.192B vs $723M; acquisitions used $8.87B, buybacks $3.00B, dividends $0.16B
- Cash $3.254B vs $9.852B; debt $43.161B vs $39.384B; 2026 capital expenditures guidance $1.9B–$2.1B
Risk Factors
- No material changes to risk factors from the December 31, 2025 Form 10-K
- Debt documentation update: February 4, 2026 credit-agreement extension
- Capital-allocation risk: $4.869 billion spent repurchasing shares in first-quarter 2026
- Remaining share-repurchase authorization: $2.000 billion under the November 6, 2025 program
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Thermo Fisher Scientific quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.